Common Red Flags in Peptide Documentation

The most actionable red flags are often simple: batch numbers differ across the label and COA, sample names do not resolve to the batch, or acquisition dates occur after document approval. These conflicts break the evidence chain.

Not every mismatch indicates misconduct; formatting, customer codes and corrected metadata can explain differences. The supplier should provide a controlled mapping or revision trail rather than an undocumented verbal assurance.

Repeated chromatogram shapes, identical noise patterns or unchanged acquisition timestamps across purportedly different batches warrant investigation. Cropped axes, missing integration marks and absent method information prevent meaningful review.

Mass spectra should show plausible charge states and mass calculations for the stated molecule. A highlighted expected value without raw spectral context is weaker than linked evidence from the principal chromatographic peak.

Watch for molecular formulae, theoretical masses or sequences that belong to another product. Templates can improve consistency, but stale fields reveal weak review when they survive final approval.

Unsupported claims such as universal stability, undefined grade or compliance statements outside a certificate's scope should be separated from measured results. Technical records should state evidence and limits rather than marketing conclusions.

Create a discrepancy list that cites the file, field and expected relationship. Ask for source records, explanation, impact assessment and a corrected controlled document where needed.

Evaluate the quality of the response as evidence about the supplier system. Transparent root-cause analysis and preserved revision history are stronger than a rapidly replaced PDF with no explanation.